Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4(*)0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1-expressing melanoma

Journal of Experimental Medicine

Volumn 191, Issue 4, 2000, Pages 625-630

  Jäger, Elke ^a   Jäger, Dirk ^a,b   Karbach, Julia ^a   Chen, Yao Tseng ^b,c   Ritter, Gerd ^c   Nagata, Yasuhiro ^c   Gnjatic, Sacha ^c   Stockert, Elisabeth ^c   Arand, Michael ^d   Old, Lloyd J ^c   Knuth, Alexander ^a  

^a KRANKENHAUS NORDWEST   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

HLA class II restricted NY ESO 1 epitopes CD4+ T cell recognition

Indexed keywords

EPITOPE; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; MELANOMA; PRIORITY JOURNAL; T LYMPHOCYTE;

ALLELES; AMINO ACID SEQUENCE; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; HLA-DR ANTIGENS; HUMANS; MELANOMA; MEMBRANE PROTEINS; MOLECULAR SEQUENCE DATA; PROTEINS; RECOMBINANT PROTEINS;

EID: 0034695886     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.191.4.625     Document Type: Article

References (24)

1. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
2. A survey of the humoral response of cancer patients to a panel of human tumor antigens
3. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
4. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo: Implications for tumor vaccines with melanoma associated antigens
5. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
6. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens
7. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II-negative tumors
8. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells
9. + T cells
10. Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene
11. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes
12. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11
13. The role of CD4+ T cell responses in antitumor immunity
14. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+, 2- T cells. Tumor eradication does not require participation of cytotoxic T cells
15. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai vires infection
16. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes
17. + T cell help
18. Help for cytotoxic T cell responses is mediated by CD40 signalling
19. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
20. High level IL-12 production by routine dendritic cells: Upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10
21. Ligation of CD40 on dendritic cells triggers production of high levels of IL-12 and enhances T cell stimulatory capacity: T-T help via APC activation
22. Development of Th1 CD4+ T-cells through IL-12 produced by Listeria-induced macrophages
23. B cells inhibit induction of T cell-dependent tumor immunity
24. Humoral immune responses of cancer patients against 'Cancer-Testis' antigen NY-ESO-1: Correlation with clinical events